INTRODUCTION
Transmissible spongiform encephalopathies (TSEs), or prion diseases, encompass a group of fatal neurodegenerative diseases in animals and man, which can be transmitted experimentally to laboratory rodents and primates. The onset of clinical illness is preceded by a long incubation period of months to decades, during which time there is no indication of infection. Associated with TSEs is the accumulation of an abnormally folded conformer (PrP Sc ) of a host-encoded cellular prion protein (PrP C ) predominantly in the brains of affected animals and humans. PrP Sc not only serves as a biomarker for these diseases, but its relative resistance to proteolysis and detection has been the major focus in the development of most immunologically based TSE diagnostic tests. Post-mortem neuropathological and immunohistochemical (IHC) examination of brain tissue from an animal or human has remained the 'gold standard' of TSE diagnosis. Although they are very specific (van Keulen et al., 1995 Keulen et al., , 1996 Wells & Wilesmith, 1995; Gavier-Widen et al., 2005) , these methods are ill-suited to rapid, routine analysis. In addition, diagnosis of TSEs is difficult, since the highest concentrations of the TSE agents are found in the nervous system tissues and very low concentrations in easily accessible body fluids such as blood or urine.
To facilitate preclinical detection of TSEs in peripheral tissues, notably blood, the target PrP Sc in a sample can be amplified by means of protein misfolding cyclic amplification (PMCA) (Saborio et al., 2001) . PMCA has been reported to increase the sensitivity of the detection of PrP Sc from brains of infected rodents (Saborio et al., 2001; Bieschke et al., 2004; Deleault et al., 2005) , cattle and sheep (Soto et al., 2005) , humans with Creutzfeldt-Jakob disease (Jones et al., 2007) and deer with chronic wasting disease (CWD) (Kurt et al., 2007) . Furthermore, PMCA has been reported to detect PrP Sc in sheep and hamster blood, both at terminal stages of disease and in pre-symptomatic animals (Castilla et Thorne & Terry, 2008) and in urine and cerebrospinal fluid (Atarashi et al., 2007 (Atarashi et al., , 2008 Murayama et al., 2007) making this technology a useful diagnostic tool. However, to date PMCA is hindered by the need for many rounds of cycling in order to visualize the final product by immunoblotting.
We have recently reported (Chang et al., 2009 ) the development of a sensitive immunoassay, termed the surround optical fibre immunoassay (SOFIA), for the detection of PrP Sc . This assay has been used for the detection of PrP Sc from the brains of clinical scrapieinfected sheep, CWD-infected cervids and TSE-infected small laboratory animals. An important aspect of this assay platform is the combination of several unique monoclonal antibodies (mAbs), along with the instrumentation hardware, which allows for the detection of PrP Sc without the need to remove PrP C by proteinase K (PK) pre-treatment. The sensitivity of this assay underscores its potential utility as both a preclinical assay for PrP Sc in the central nervous system (CNS) and a non-invasive ante-mortem assay for TSEs using body fluids. The ability to successfully and reliably assay for prion diseases using body fluids is a concern, since it is dependent on both the sensitivity of an assay and the levels of target to be detected. By combining SOFIA with limited PMCA, we now report the ability to detect PrP Sc in the blood from both preclinical and clinical scrapie sheep and CWD deer.
RESULTS
The three PrP mAbs used in this study (5D6, 11F12 and 8E9) have been described previously (Chang et al., 2008 (Chang et al., , 2009 . Since immunoprecipitation (IP) with mAb 8E9 serves as a bridge linking PMCA and SOFIA, we examined the utility of this mAb for PrP IP. Mixtures of various ratios of 10 % brain homogenates from uninfected and infected hamsters (top panel), sheep (middle panel) and deer (bottom panel) [uninfected : infected (%) -100 : 0, 90 : 10, 70 : 30, 50 : 50] were immunoprecipitated and analysed by Western blotting (WB) (Fig. 1) . In the absence of PK digestion, all samples, regardless of the brain homogenate ratios, showed similar immunostaining intensities (lanes 1-4). WB of PK-treated immunoprecipitants (lanes 5-8) demonstrated similar immunostaining when directly compared to samples containing only PKtreated infected brain homogenates (data not shown). These results indicate that mAb 8E9 immunoprecipitated both PrP C and PrP Sc and the presence of PrP C did not inhibit or reduce maximal PrP Sc IP. To quantitatively and qualitatively evaluate the PrP isolated, capture ELISA was performed on mAb 8E9 immunoprecipitants from the combinations of PK-untreated normal brain homogenates (hamster, sheep and deer) with their respective prioninfected (263K-infected hamster brain, scrapie sheep brain and cervid CWD brain homogenates) counterparts (Fig. 2) . The capture ELISA utilized the same mAb pair (11F12 as the capture mAb and 5D6 as the detector mAb) as that used for SOFIA. mAb 8E9 IP of the normal brain : infected brain combinations followed by capture ELISA resulted in increasing ELISA signal intensities as the levels of infected brain material increased in the starting mixtures. Since neither the normal nor the infected brain material was proteolytically digested, each mixture contained either PrP C alone or a mixture of both PrP C and PrP Sc , as confirmed by WB (Fig. 1) . However, analysis of the immunoprecipitants by the capture ELISA indicated that the increasing signal intensities were dependent on the Fig. 1 . WB analysis of PrP following mAb 8E9 IP. Normal brain homogenates (NBH) (10 %) were combined with prion-infected brain homogenates (IBH) from clinical animals of the corresponding species [263K-infected hamster brain (top panel), scrapie sheep brain (middle panel), CWD-infected deer brain (bottom panel)] in various proportions (lanes 1 and 5, NBH only; lanes 2 and 6, 90 ml NBH+10 ml IBH; lanes 3 and 7, 70 ml NBH+30 ml IBH; lanes 4 and 8, 50 ml NBH+50 ml IBH) and immunoprecipitated with mAb 8E9. The immunoprecipitated samples were either untreated (lanes 1-4) or PK-treated (lanes 5-8) prior to WB and immunostaining with mAb 11F12. The ability to detect PrP Sc in blood from 263K-infected hamsters and scrapie sheep samples following serial PMCA (sPMCA) has previously been reported (Soto et al., 2005; Saa et al., 2006; Thorne & Terry, 2008) . However, the large number of PMCA cycles necessary for PrP Sc detection makes the technique impractical for use as a diagnostic assay. We have approached the issue of PrP Sc detection in blood by incorporating sPMCA, followed by IP of the amplified target and detection with the sensitive SOFIA assay (Chang et al., 2009) . sPMCA was evaluated and validated using hamster brain (Fig. 3a) . As described in Methods, 10
28
-10 211 dilutions (relative to the original brain tissue) of 10 % 263K-infected hamster brain homogenate were subjected to sPMCA using normal hamster brain homogenate as a PrP C source. PrP Sc was undetectable at all the dilutions following seven cycles of sPMCA, but it could be detected in the 10 28 diluted sample by the completion of 14 cycles (Fig. 3, Sc compared with infected hamster brain, the levels of amplification were still approximately 4 logs relative to the initial PrP Sc levels (not shown).
Plasma from scrapie sheep and CWD deer were subjected to sPMCA 40 . The sheep samples consisted of three groups (Table 1 , groups 1-3) of scrapie sheep, which, at the time of blood collection, were differentiated based on the presence or absence of clinical signs and PrP Sc IHC staining of third eyelid lymphoid follicles (Fig. 4) . All animals in group 3 that did not display clinical symptoms at the blood collection time points eventually progressed to clinical disease. The group of uninfected sheep (Table 1 , group 4) were housed and maintained in an isolated, scrapie-free area. CWD samples consisted of several experimentally infected (oral route) preclinical and clinical white-tailed deer ( Table 2 ). All of the sheep and CWD samples were individually subjected to sPMCA 40 and analysed by both capture ELISA and WB following PK digestion. No PrP Sc was detected in any of the plasma samples tested following sPMCA 40 by either capture ELISA or WB even after concentration by mAb 8E9 IP. The addition of polyadenylic acid [poly(A)], which has been reported to facilitate rapid detection of low levels of PrP Sc from sheep blood (Thorne & Terry, 2008) , did not improve amplification efficiency to the point of PrP Sc detection by WB from scrapie sheep or CWD deer plasma following sPMCA 40 . The lack of PrP Sc detection following sPMCA 40 from sheep blood was independent of the sheep genotypes used (Table 1) . That is, the pairing of sheep genotypes between the source of PrP Sc and the normal sheep brain PrP C did not sufficiently increase the amplified product for detection by immunoblotting. Since WB was not informative, it is unclear whether PrP
Sc was initially present in the blood from CWD and any of the animals comprising the three groups of scrapie sheep or whether PMCA was Diagnosis of prion diseases using blood successful, but WB was not sensitive enough to detect the amplified PrP Sc after only 40 cycles. It has been reported that PMCA of sheep blood could lead to false-positive results due to the apparent spontaneous generation of PrP Sc (Thorne & Terry, 2008) . Therefore, rather than continue increasing the number of PMCA cycles, we utilized SOFIA (Chang et al., 2009) 
for PrP
Sc detection of untreated and PK-treated mAb 8E9 immunoprecipitated sPMCA 40 products. Our studies demonstrated that in the absence of sPMCA 40 , the readings obtained by SOFIA from scrapie sheep and uninfected sheep plasma samples were similar and approached baseline levels (Fig. 5 ). Prior to sPMCA 40 , the SOFIA signal intensities (sample/background) for the individual samples ranged from 0.5-0.9 (group 1), 0.7-1.2 (group 2), 0.8-1.3 (group 3) to 0.6-1.1 (group 4). Since previous studies on the dynamic range of SOFIA (Chang et al., 2009 ) demonstrated that in PKuntreated clinical sheep brain PrP Sc was detectable in the femtomole range (Chang et al., 2009) , it is likely that the levels of PrP Sc in scrapie sheep plasma samples are below the detectable range. In an attempt to amplify the levels of PrP Sc to within the dynamic range of SOFIA, we first performed sPMCA 40 followed by mAb 8E9 IP. Non-PKtreated PrP Sc could be detected by SOFIA on the immunoprecipitated sPMCA 40 products (Fig. 5) . Following sPMCA 40 , the range of signal intensities (0.7-1.2) for the individual samples of the control group (group 4) did not significantly differ from those samples prior to PMCA. However, the range of SOFIA signal intensities for all three groups of scrapie sheep were similar to each other (group 1: 4.3-4.8, group 2: 4.4-5.1 and group 3: 4.8-5.3), regardless of their clinical manifestations, and significantly greater than both the pre-PMCA values as well as the uninfected samples (group 4). The value of this approach is realized when one considers that confirmation of disease was dependent on the sheep being scrapie infected, but was independent of the presence of clinical signs and the neuropathology, as all three groups of sheep tested positive for the presence of PrP Sc (Fig. 5) . We observed that PrP Sc amplification was also independent of genotype compatibility, since there was no difference in the amplification when normal brain homogenates from either ARQ/ARQ or ARQ/VRQ sheep were used with any of the infected sheep plasma samples. Furthermore, the need for PK digestion to distinguish PrP C from PrP Sc was unnecessary, since the results of SOFIA were the same regardless of whether the sPMCA 40 products were untreated or PK-treated (Fig. 5) prior to IP and immunoassay analysis.
Similar studies were carried out with plasma obtained from several preclinical and clinical cases of CWD deer (Fig. 6) . Similar to the sheep plasma samples described above, the signals obtained by SOFIA on the CWD samples in the absence of sPMCA 40 did not differ from the uninfected controls, which themselves approached background. In addition, PK-resistant PrP Sc could not be detected by either capture ELISA or WB following sPMCA 40 . However, following IP of the sPMCA 40 products, and regardless of whether the immunoprecipitants were PK digested or not, . PrP Sc detection in scrapie sheep blood samples using SOFIA with and without PMCA. Plasma samples were divided into three groups according to the appearance of clinical signs and IHC associated with scrapie sheep. Each plasma sample was subjected to PMCA 40 or incubated without PMCA. Each PMCA product was either untreated or PK digested followed by mAb 8E9 IP and analysed for PrP Sc by SOFIA. Plasma samples from each of the three groups were assayed in triplicate and the data for all the samples in each group combined and expressed as mean±SD. and without PMCA. Each of the plasma samples from the five CWD cases was first subjected to PMCA 40 or maintained in the absence of PMCA. All PMCA products were either undigested or PK treated followed by mAb 8E9 IP and SOFIA. Values represent the mean of triplicate assays±SD. In the case of the four uninfected deer plasma samples, each of the four samples was analysed in triplicate and the combined results of the four samples are expressed as the mean±SD.
Diagnosis of prion diseases using blood
PrP Sc was detectable by SOFIA from all preclinical and clinical CWD plasma (Fig. 6) . Furthermore, similar to the scrapie sheep samples, the SOFIA values were dependent on the samples originating from infected animals, but confirmation of disease by SOFIA was independent of the clinical status of the diseased animal.
DISCUSSION
Prion diseases are typically diagnosed after the infection has advanced, significantly reducing the possibility of successful intervention and the ability to prevent introduction of infected material into the human food chain.
Studies have shown that blood carries the infectious agent both in the symptomatic and pre-symptomatic stages of the disease in experimentally infected and naturally produced disease (Houston et al., 2000; Holada et al., 2002; Brown, 2005; Castilla et al., 2005b; Saa et al., 2006) . Furthermore, although blood from vCJD-infected patients is clearly infectious (Llewelyn et al., 2004; Peden et al., 2004; Wroe et al., 2006) , its concentration of infectious material is much lower than that in the CNS, and it follows that the concentration of PrP Sc is also extremely low. In addition, it is possible that some infected patients may never develop clinical symptoms, but will remain asymptomatic carriers who can potentially transmit the disease. Several studies indicate that infectious material is in the white blood cells, but the plasma is also infectious (Cervenakova et al., 2003) . In a healthy individual, significant levels of PrP C are present in white blood cells, red blood cells, platelets and plasma, probably at much higher concentrations than PrP Sc . Also, the biochemical properties of PrP Sc in the different blood fractions is unknown. Given its low concentration and its environment, it is not certain if PrP Sc can form aggregates resistant to PK, the treatment on which most current rapid tests are based. These issues have been addressed with SOFIA, a laser-based immunoassay that we have developed for the detection of brain PrP Sc (Chang et al., 2009 ). SOFIA's sensitivity and specificity (Chang et al., 2009) eliminates the need for PK digestion to distinguish between the normal and abnormal PrP isoforms.
Detection of PrP
Sc in blood is consistent with the demonstration of infectivity by blood transfusion from infected sheep (Houston et al., 2000; Hunter et al., 2002) in which disease was transmitted in both the plasma and buffy coat fractions from symptomatic and pre-symptomatic animals. PrP Sc was detected in the blood from experimentally infected hamsters with 89 % sensitivity following .800 PMCA cycles (Castilla et al., 2005b) . Soto et al. (2005) indicated that PMCA could be applied successfully to sheep with natural scrapie with low levels of amplification (86) after 10 cycles. Furthermore, it has been demonstrated (Thorne & Terry, 2008) (Thorne & Terry, 2008) . However, since those investigators used blood exclusively from clinical scrapie VRQ/VRQ sheep, they could not evaluate the influence of other genotypes in their blood studies. In sheep, susceptibility to classical scrapie disease is partly controlled by polymorphisms of the PrP gene. Thus, sheep bearing the VRQ residues (at codons 136, 154 and 171) are highly susceptible to the classical form of scrapie, while those bearing ARQ appear to have intermediate susceptibility and homozygous ARR sheep are relatively resistant (Hunter et al., 1993; Goldmann et al., 1994) . In our studies, we did not find differences in genotype to be a factor in plasma PrP Sc amplification efficiency, although none of the genotypes we used was VRQ/VRQ.
Our studies demonstrate the detection of PK-untreated PrP Sc in plasma from naturally and experimentally infected clinical and preclinical scrapie sheep and CWD whitetailed deer. In contrast to previous studies, we added PrP C at the start of each 1 h cycle to improve the levels of amplification. It has previously been reported that the efficiency of sheep PrP Sc amplification was improved by several logs when control sheep brain homogenate was replenished more frequently (Thorne & Terry, 2008) . In our studies, although 40 cycles of sPMCA combined with IP was inadequate for PrP Sc detection by ELISA or WB, the PrP Sc could readily be measured by the highly sensitive SOFIA method. The limited number of cycles necessary for our assay platform virtually eliminates the possibility of obtaining PMCA-related false-positive results as previously reported (Thorne & Terry, 2008) .
Although the CWD infectious agent has been detected in saliva, blood, urine and faeces, the direct immunodetection of PrP Sc from this material has been unsuccessful (Haley et al., 2009a, b) Furthermore, the successful detection of the CWD infectious agent for some of this material required bioassays of the sPMCA products (Mathiason et al., 2006 (Mathiason et al., , 2009 Haley et al., 2009a, b; Tamguney et al., 2009) . We have demonstrated a more rapid direct immunodetection of CWD PrP Sc utilizing a combination of PMCA and SOFIA. A previous study reported the use of a PMCA-like amplification immunoassay, Am-A-FACTT, to detect PrP Sc aggregates in the plasma of infected, but asymptomatic, deer and elk infected either naturally or experimentally with the CWD agent (Chang et al., 2007) .
The current dogma is that PrP
Sc directly correlates with infectivity and its accumulation in the brain causes neuropathology and clinical disease. It is also assumed that the rate and pattern of PrP Sc accumulation, and, therefore, the rate of formation of neuropathology, determines the incubation periods of the disease (Prusiner et al., 1990; Carlson et al., 1994) . However, it has also been shown that in the CNS and contrary to expectation, overall accumulation of PrP Sc and infectivity to a high level can be present in asymptomatic mice (Bueler et al., 1994) . Additional studies on naturally and experimentally infected sheep (Madec et al., 2004; Bulgin et al., 2006) have also demonstrated inconsistencies between the levels of PrP Sc , IHC staining topology, extent of histological lesions and clinical disease. In the present study, the SOFIA values, which measure and are proportional to the levels of sPMCA 40 -amplified PrP Sc , were similar for both preclinical and clinical cases when compared within a given species. Therefore, it appears that the level of PrP Sc in plasma does not correlate with the extent of clinical disease. Murayama et al. (2007) examined PrP Sc levels in plasma and buffy coat fractions and demonstrated that PrP Sc could be amplified from plasma of infected hamsters only after PrP Sc was detectable in the brains. This suggested that, at least in hamsters, PrP Sc might leak into the plasma from the infected brain due to destruction of the blood-brain barrier. The source of PrP Sc in the buffy coats during the asymptomatic stage appeared to be the spleen and other lymphoid organs, as suggested previously (Saa et al., 2006) . Based on the limits of detection previously reported for scrapie sheep and CWD deer brain PrP Sc (Chang et al., 2009 ) and the amplification of PrP Sc in infected sheep and deer plasma reported in this paper, there is less than 1 attogram per ml of plasma of PrP Sc from sheep and deer.
Plasma PrP Sc may differ from brain PrP Sc in its conformation and aggregation properties. Yakovleva et al. (2004) reported that PK digestion of plasma from vCJDinfected mice resulted in a significant decrease in infectivity and suggested the existence, in plasma, of PK-sensitive isoforms of PrP Sc . Furthermore, not all protease-resistant PrP molecules carry prion infectivity. Indeed, in vitro conversion experiments of PrP C to PrP Sc , in which protease resistance was achieved by a denaturation-renaturation procedure, resulted in a protease-resistant but not infectious PrP isoform (Kocisko et al., 1994; Hill et al., 1999) . Alternatively, plasma PrP Sc may resemble the new protease-resistant soluble isoform that is associated with very low levels of infectivity, as has already been reported in urine (Shaked et al., 2001) . It is also possible, but unlikely, that there is a subset of PrP Sc in the blood which is independent of clinical disease progression and remarkably constant, that is more amenable to PMCA compared with the CNS PrP Sc present.
Our studies have demonstrated the ante-mortem detection of PrP Sc and the diagnosis of prion diseases from naturally and experimentally infected animals. The ability of this assay to diagnose scrapie sheep in preclinical sheep that were IHC positive suggests that this assay compares in sensitivity and specificity to IHC detection of prion diseases. This finding, together with the confirmation of disease in symptomatic but IHC-negative animals, points to the potential utilization and versatility of this assay for disease surveillance. Several issues which now need to be addressed include: (i) correlation of disease infection and progression with PrP Sc detection in blood, and possibly urine, through time-course studies, (ii) the ability to use this assay platform for the screening of blood and tissues prior to their use in a variety of applications (i.e. medical, pharmaceutical or cosmetic) and (iii) applicability of this assay platform for the preclinical diagnosis of, as well as confirmatory evidence of clinical, human prion diseases.
METHODS Samples
Hamsters. Brain tissue from uninfected and clinical hamsters infected with the 263K hamster-adapted scrapie strain was obtained as described previously (Chang et al., 2008) .
Sheep. Experimental oral infections used a 20 % scrapie sheep brain homogenate (derived from a composite of seven scrapie brains from clinically and immunohistochemically positive animals) prepared in PBS. All uninfected animals were housed in a separate scrapie-free facility. Clinical signs of sheep scrapie included: fine head tremors progressing to body trembling, wool loss from rubbing, nibbling at extremities, hypersensitivity and gait abnormalities. Genotyping of the sheep was performed commercially (Gene Check).
For IHC, formalin fixed third eyelid tissues were washed for 15 min in water and soaked in 99 % formic acid for 1 h. After a 3 h water wash, the tissues were paraffinized in a Microm STP 120, and cut at 4 micrometres. Slides were dried for 24 h, deparaffinized and immunostained using the Ventana proprietary reagents (Ventana Medical Systems) (prion enhancing solution and anti-PrP antibody) and Benchmark LT automated system. For blood collection (IACUC approved), the animals were restrained and a needle was inserted into the jugular vein. Following blood collection in sodium citrate, one half of the blood was shipped immediately. The remaining half of the collected whole blood sample was centrifuged at low speed for 15 min at 4 uC. Plasma was removed, frozen and shipped on dry ice.
Deer. White-tailed deer care and sampling protocols followed IACUC-approved established protocols (Wild & Miller 1991; Wild et al. 1994) . Food, water and supplements were provided ad libitum in all paddocks. At about 6 months of age, fawns were orally inoculated with about 0.5 g conspecific, pooled, infectious brain material containing 6 mg PrP CWD (brain tissue) g 21 (Raymond et al. 2000; Wolfe et al. 2007 ). All deer were evaluated by a veterinarian experienced in recognizing clinical signs of CWD, and subjectively scored for behavioural changes, loss of body condition, ataxia, and salivation or polydipsia. The five deer used for this study were heterozygous for glycine and serine at codon 96 of the native prion protein gene, had PrP CWD accumulation in tonsil biopsies by 253 or 343 days post-infection (p.i.) (Wolfe et al. 2007) , and were confirmed to be prion infected at post-mortem examination at 891-1774 days p.i.
Blood samples were collected from the five inoculated white-tailed deer at 891 days p.i. At the time of sampling, one animal (BC04) was in the end-stage clinical CWD, two (N204 and W1004) were showing some loss of body condition, and the other two (I304 and K304) were clinically normal. For blood sampling, deer were sedated with xylazine, skin overlying the jugular vein was aseptically prepared and blood was collected via jugular venepuncture into a plastic bag treated with sodium citrate. Bags of blood were cooled and shipped overnight.
IP. MagnaBind protein G beads (Pierce) (50 ml 5 mg stock ml 21 ) were washed three times with PBS, resuspended in 50 ml PBS and 200 ml 10 % brain homogenate was added with 50 mg mAb 8E9 (10 mg ml 21 ) in a total volume of 1.2 ml PBS. After mixing at room temperature for 1 h, the beads were magnetically separated, washed three times with PBS containing 0.2 % Tween 20 (PBST) and then resuspended in 600 ml PBS. After heating at 100 uC for 10 min and microcentrifugation at 16 000 g for 3 min, the supernatants were used for capture ELISA.
For blood samples, 100 ml MagnaBind protein G beads (5 mg stock ml 21 ) were resuspended in 100 ml PBS, followed by the addition of 100 mg mAb 8E9 in a final volume of 5 ml PBS and mixed at room temperature for 1 h. The beads were washed with PBST, resuspended in 5 ml PBS containing 500 ml plasma and incubated for an additional 1 h. As described for brain, the beads were isolated, washed in PBST, heated and the microcentrifuged supernatant analysed by capture ELISA.
ELISA. For capture ELISA, wells were coated with 100 ml PBS-diluted mAb 11F12 (5 mg ml 21 ) and incubated overnight at 4 uC. After washing the wells with PBST and blocking with 3 % BSA/PBS (3 h at room temperature), 100 ml of the supernatants was added to each well. Following a 1 h incubation and PBST wash, 100 ml biotinylated (EZ-Link Sulfo-NHS-LC-Biotinylation kit; Pierce) mAb 5D6 (4 mg ml 21 ) was added to each well (1 h at 37 uC) followed by 100 ml streptavidin-conjugated to alkaline phosphatase (0.2 mg ml 21 final conc.) (1 h at 37 uC). After a PBST wash and addition of 100 ml reconstituted pNPP (Sigma) substrate for 30 min, the absorbance (A 405 ) was read with a Bio-Tek microplate reader.
PMCA. As a source of PrP C for sPMCA of both brain and blood, 10 % (w/v) brain homogenates from normal hamsters, sheep and deer [prepared in PBS containing 150 mM NaCl, 1.0 % Triton X-100, 4 mM EDTA and complete protease inhibitor cocktail (Calbiochem)] were centrifuged (1500 g, 30 s) and the supernatants quick frozen. A 500 ml aliquot of serial 10-fold dilutions (10 28 -10 211 ) of brain homogenates from 263K-infected hamster, scrapie sheep and CWD deer were mixed with 100 ml of the 10 % normal brain supernatant from the corresponding species and incubation (1 h at 37 uC with shaking). Each sample was then sonicated (Sonics-VC750 at 28 W power output) followed by the addition of another 100 ml of 10 % normal brain homogenate and incubated (1 h at 37 uC with shaking). This was defined as one cycle of amplification. After each round of five cycles, PMCA was continued by transferring 500 ml of the PMCA reaction mix from the original reaction tube to a new tube and adding 100 ml of 10 % normal brain homogenate (in PBS). PMCA on 500 ml aliquots of undiluted scrapie sheep or CWD deer plasma was carried out similarly as described for brain. Following PMCA, samples were centrifuged at 2000 g for 10 min. For brain samples, 200 ml of supernatant was digested with PK (100 mg ml 21 , 30 min at 50 uC), followed by the addition of 1 % protease inhibitor cocktail and 1 % SDS. Samples were heated at 100 uC for 10 min and 10 ml aliquots were analysed by WB (Chang et al. 2009 ). For blood, following PMCA 500 ml of amplified blood samples were either untreated or PK-treated followed by mAb 8E9 IP prior to analysis by WB or SOFIA. For all PMCA samples, dilutions were expressed relative to the original undiluted brain or blood samples. Blood samples not subjected to PMCA were immunoprecipitated and processed similarly as above without the sonication and 37 uC incubation cycling.
SOFIA. Ninety-six well High Binding plates (Costar) were coated with capture mAb 11F12 (100 ml per well at 5 mg ml 21 ) at room temperature for 3 h and blocked with 1 % (w/v) casein in TBS overnight at 4 uC. Magnetic protein G beads and mAb 8E9 in a total volume of 800 ml were mixed for 60 min, washed three times with PBST and the pellets resuspended in 800 ml PBS. Blood samples were centrifuged (800 g, 5 min) and 800 ml of the supernatants were combined with SDS (1 % final conc.), heated at 100 uC for 10 min, mixed with 800 ml protein G beads-mAb 8E9 for 1 h and washed three times with PBST. The final washed pellets were resuspended in 800 ml PBS and heated for 10 min. After centrifugation at 16 000 g for 5 min, 100 ml of supernatant was added to each well. After incubation at room temperature (1 h) and washing with PBST, 100 ml biotinylated mAb 5D6 (4 mg ml
21
) was added for 1 h, followed by washing and incubation with 100 ml (1 : 1000) streptavidin-rhodamine red-X conjugate (Invitrogen) for 1 h. After four PBST washes, 100 ml 1 M NaOH was added and the plates were heated (10 min at 100 uC), mixed for 30 min at room temperature and neutralized with equimolar amounts of HCl. Aliquots (90 ml) were transferred to 100 ml microcaps (Drummond Scientific Co.), and then inserted into a custom capillary sample holder for laser analysis.
